<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781181</url>
  </required_header>
  <id_info>
    <org_study_id>AcibademU</org_study_id>
    <nct_id>NCT02781181</nct_id>
  </id_info>
  <brief_title>Carotid Artery Stenting Without Protection</brief_title>
  <official_title>Carotid Artery Stenting Without Embolic Protection: A Randomized Multicenter Trial (the CASWEP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A recent randomized Carotid artery stenting (CAS) trial in which carotid protection device
      (CPD)s were used to demonstrate equivalence with carotid endarterectomy (CEA) by achieving
      noninferiority regarding periprocedural risk. However, the clinical efficacy and safety of
      CPDs are still a matter of controversy. It has been argued that the limited reduction
      provided by CPDs may be due to the devices themselves. Probably, they serve as sources for
      emboli during the procedure or removal technique. In general, 30- day adverse outcome for CAS
      with the use of CPDs seems not to be different from the outcome without CPDs.

      Thus, the main goal in this study is to test the hypothesis that CAS without CPD usage is as
      safe as in those patients who undergo CAS with CPD neuroprotection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Carotid Artery Stenting without Embolic Protection (CASWEP) trial is designed in a
      prospective, randomized, multi-center fashion to determine if CAS without CPD is feasible and
      safe in patients with symptomatic or asymptomatic severe carotid stenosis.

      Study participants After the exclusion criterias were applied 279 patients were divided as
      139 patients in the CAS with CPD arm and 140 patients in the CAS without CPD arm. Our study
      population includes patients with severe carotid artery stenosis referred to the 3 study
      center hospitals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients experiencing new ischemic brain lesions on diffusion-weighted magnetic resonance imaging (DWMRI), transient ischemic attack (TIA), Stroke and death events.</measure>
    <time_frame>through hospital admission, an average of 2 days</time_frame>
    <description>peri-procedural in hospital outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Carotid Arteries</condition>
  <arm_group>
    <arm_group_label>CAS with CPD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CAS performed under neuroprotection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAS without CPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAS without neuroprotection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAS with CPD</intervention_name>
    <description>using a neuroprotection device</description>
    <arm_group_label>CAS with CPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAS without CPD</intervention_name>
    <description>No Neuroprotection</description>
    <arm_group_label>CAS without CPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patients with ≥ 50% ipsilateral carotid stenosis by angiography, ≥70% by
             duplex ultrasound, or ≥70% by Computerized tomography (CT) angiography or Magnetic
             Resonance (MR) angiography if the stenosis on ultrasonography was 50% to 69%.

          -  Asymptomatic patients with ≥60% stenosis by angiography, ≥70% by ultrasound, or ≥80%
             by CT angiography or MR angiography if the stenosis on ultrasonography was 50% to 69%.

        Exclusion Criteria:

          -  Total occlusion,

          -  Visible thrombus at the lesion site

          -  Bleeding diathesis

          -  Cerebral vascular malformation,

          -  Degenerative cerebral diseases

          -  Cerebral tumors

          -  Illness impeding informed consent

          -  Life expectancy&lt;2 years

          -  Previous CEA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SEVKET GORGULU, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adapazari Education and Research Hospital</name>
      <address>
        <city>Adapazari</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adiyaman University</name>
      <address>
        <city>Adiyaman</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem University</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koşuyolu Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehmet Akif Ersoy Education and Training Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stenting</keyword>
  <keyword>Protection device</keyword>
  <keyword>EPD usage</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

